Biogen Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BIIB Nasdaq 2830 www.biogen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biogen Inc.

Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know - Jul 18th, 2025 1:11 pm
Here's What to Expect From Biogen's Next Earnings Report - Jul 18th, 2025 6:21 am
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Jul 17th, 2025 5:00 am
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States - Jul 17th, 2025 5:00 am
The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association - Jul 16th, 2025 1:53 am
Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors - Jul 15th, 2025 2:00 am
Amyotrophic Lateral Sclerosis (ALS) Market Analysis Report 2025-2035 | Increase in Clinical Trials and Investments will Accelerate the Development of Innovative Treatments - Jul 14th, 2025 2:01 am
RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT - Jul 10th, 2025 9:14 am
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - Jul 10th, 2025 5:00 am
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - Jul 10th, 2025 5:00 am
Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT - Jul 9th, 2025 10:39 pm
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review - Jul 8th, 2025 7:59 am
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? - Jul 3rd, 2025 6:17 am
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease - Jul 1st, 2025 8:50 am
3 Reasons BIIB is Risky and 1 Stock to Buy Instead - Jun 30th, 2025 10:03 pm
AbbVie to buy Capstan for up to $2.1 billion in immunology push - Jun 30th, 2025 6:42 am
RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market - Jun 30th, 2025 6:18 am
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy - Jun 30th, 2025 5:30 am
Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials - Jun 28th, 2025 8:05 am
Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results - Jun 28th, 2025 2:16 am